ESCRT-III Component CHMP4C Attenuates Cardiac Hypertrophy by Targeting the Endo-Lysosomal Degradation of EGFR
Ao Liu,Huilin Xie,Fangyan Tian,Peiyuan Bai,Haobo Weng,Yu Liu,Wen Liu,Lu Tang,Hongmin You,Nianwei Zhou,Xianhong Shu,Ao LiuHuilin XieFangyan TianPeiyuan BaiHaobo WengYu LiuWen LiuLu TangHongmin YouNianwei ZhouXianhong ShuDepartment of Echocardiography,Zhongshan Hospital,Fudan University,Shanghai Institute of Cardiovascular Diseases,China. (A.L.,H.X.,F.T.,H.W.,Y.L.,W.L.,L.T.,N.Z.)Department of Cardiology,Zhongshan Hospital,Fudan University,Shanghai Institute of Cardiovascular Diseases,China. (A.L.,H.X.,P.B.,H.W.,X.S.)Department of Ultrasound Medicine,The Affiliated Hospital of Guizhou Medical University,Guiyang,China (F.T.).Department of Cardiology,Changhai Hospital,Naval Medical University,Shanghai,China (H.Y.).Department of Echocardiography,Shanghai Xuhui District Central Hospital,China (X.S.).
DOI: https://doi.org/10.1161/hypertensionaha.123.21427
IF: 9.8968
2023-10-18
Hypertension
Abstract:Hypertension, Ahead of Print. BACKGROUND:Cardiac hypertrophy and subsequent heart failure impose a considerable burden on public health worldwide. Impaired protein degradation, especially endo-lysosome-mediated degradation of membrane proteins, is associated with cardiac hypertrophy progression. CHMP4C (charged multivesicular body protein 4C), a critical constituent of multivesicular bodies, is involved in cellular trafficking and signaling. However, the specific role of CHMP4C in the progression of cardiac hypertrophy remains largely unknown.METHODS:Mouse models with CHMP4C knockout or cardiadc-specific overexpression were subjected to transverse aortic constriction surgery for 4 weeks. Cardiac morphology and function were assessed through histological staining and echocardiography. Confocal imaging and coimmunoprecipitation assays were performed to identify the direct target of CHMP4C. An EGFR (epidermal growth factor receptor) inhibitor was administrated to determine whether effects of CHMP4C on cardiac hypertrophy were EGFR dependent.RESULTS:CHMP4C was significantly upregulated in both pressure-overloaded mice and spontaneously hypertensive rats. Compared with wild-type mice, CHMP4C deficiency exacerbated transverse aortic constriction–induced cardiac hypertrophy, whereas CHMP4C overexpression in cardiomyocytes attenuated cardiac dysfunction. Mechanistically, the effect of CHMP4C on cardiac hypertrophy relied on the EGFR signaling pathway. Fluorescent staining and coimmunoprecipitation assays confirmed that CHMP4C interacts directly with EGFR and promotes lysosome-mediated degradation of activated EGFR, thus attenuating cardiac hypertrophy. Notably, an EGFR inhibitor canertinib counteracted the exacerbation of cardiac hypertrophy induced by CHMP4C knockdown in vitro and in vivo.CONCLUSIONS:CHMP4C represses cardiac hypertrophy by modulating lysosomal degradation of EGFR and is a potential therapeutic candidate for cardiac hypertrophy.
peripheral vascular disease